Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PK/PD of Continuous Amphotericin-B and Voriconazole in Severe Pulmonary Blastomycosis
NCT02283905Phase 4Terminated
- Sponsor
- University of Manitoba
- Start
- Jun 2015
- Primary completion
- Sep 2020
- Modality
- Lipid-based Nanoparticles, Orthosteric Ligands
- Countries
- 1
01
Overview
Phase 4, open-label, single-arm trial of liposomal amphotericin b and voriconazole in Pulmonary Blastomycosis, sponsored by University of Manitoba. Primary endpoint: Concentration-time profile of antifungals at 1 month. Started Jun 2015; status: terminated.
02
Drugs
liposomal amphotericin bvoriconazole
03
Conditions
Pulmonary Blastomycosis
Beyond the preview
Go deeper on NCT02283905.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02283905.